Cargando…

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms

SIMPLE SUMMARY: The advent of next-generation sequencing has elucidated the understanding of the genetic landscape of myeloid neoplasms. Most myeloid neoplasms carry more than one gene mutation at their initial presentation or develop them during the disease course. The patterns of and interactions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuo, Zhuang, Medeiros, L. Jeffrey, Garces, Sofia, Routbort, Mark J., Ok, Chi Young, Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Jelloul, Fatima Zahra, Garcia-Manero, Guillermo, Chien, Kelly S., Patel, Keyur P., Luthra, Rajyalakshmi, Yin, C. Cameron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855138/ https://www.ncbi.nlm.nih.gov/pubmed/36671709 http://dx.doi.org/10.3390/biology12010013

Ejemplares similares

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
por: Bannon, Sarah A., et al.
Publicado: (2021)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms
por: El Hussein, Siba, et al.
Publicado: (2022)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms
por: El Hussein, Siba, et al.
Publicado: (2022)

Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods
por: Yang, Richard K., et al.
Publicado: (2022)

Myelodysplastic/ Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-institutional Collaborative Study from the Bone Marrow Pathology Group
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2022)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience
por: El Hussein, Siba, et al.
Publicado: (2020)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Overlapping roles of spliceosomal components SF3B1 and PHF5A in rice splicing regulation
por: Butt, Haroon, et al.
Publicado: (2021)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER
por: Chien, Kelly, et al.
Publicado: (2023)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex
por: Teng, Teng, et al.
Publicado: (2017)

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
por: Adema, Vera, et al.
Publicado: (2022)

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Aung, Phyu P., et al.
Publicado: (2019)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_am1fnndho08l09kt6paako7b2v